Novo Nordisk’s Descent into the Market’s Labyrinth

Morgan Stanley’s Thibault Boutherin became the latest augur of market prophecy, demoting Novo Nordisk from “equal weight” to “underweight” with the clinical detachment of a bureaucrat stamping forms in a dimly lit chamber. His price target descended like a guillotine from 380 to 300 Danish kroner, each digit a hieroglyph in the temple of discounted cash flows. The verdict: semaglutide’s potential as an Alzheimer’s treatment had curdled into improbability, while Medicare’s looming specter threatened to unravel the pricing alchemy sustaining Ozempic’s empire.






